Tablet, Generic Name: Empagliflozin 25mg, Manufacturer: Beximco Pharmaceuticals Ltd.
🛒 How to order this item?
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Show More
Indications of Jardian 25 Tablet
To treat type 2 diabetes mellitus, Jardian 25 may be taken alone or in conjunction with other medications. It aids in lowering the elevated blood sugar levels associated with diabetes. In addition to helping avoid heart disease, this lessens the possibility of diabetes-related catastrophic consequences.
Pharmacology of Jardian 25 Tablet
Empagliflozin is an inhibitor of the sodium-glucose co-transporter-2 (SGLT-2). The SGLT2 co-transporters in the kidney are responsible for glucose reabsorption from the glomerular filtrate. SGLT2 inhibition has a glucuronic action, which inhibits renal absorption and lowers the renal glucose threshold, leading to higher glucose excretion. It also helps with weight loss and lowers blood pressure, as well as lowers hyperglycemia.
Dosage and Administration of Jardian 25 Tablet
The recommended dose of Empagliflozin is 10 mg once daily, taken in the morning, with or without food. In patients tolerating Empagliflozin, the dose may be increased to 25 mg once daily. In patients with volume depletion, correcting this condition prior to initiation of Empagliflozin is recommended.
Interaction of Jardian 25 Tablet
Empagliflozin co-administrator of Jardian 25 Tabletion with diuretics resulted in increased urine volume.
Insulin or Insulin Secretagogues: Taking Empagliflozin together with insulin or insulin secretagogues raises the risk of hypoglycemia.
Positive Urine Glucose Test: In patients with SGLT2 inhibitors, monitoring glycemic control with urine glucose tests is not suggested since SGLT2 inhibitors enhance urinary glucose excretion, resulting in positive urine glucose tests. Use different strategies to keep track of your glycemic control.
1,5-anhydroglucitol Interference (1,5-AG) Test: Using the 1,5-AG assay to monitor glycemic control is not suggested since 1,5-AG readings are inaccurate in measuring glycemic control in patients using SGLT2 inhibitors. Use different strategies to keep track of your glycemic control.
Contraindications
Patients having a history of serious allergic reactions to Empagliflozin or any of its constituents, severe renal impairment, end-stage renal disease, or dialysis should not take Empagliflozin.
Side Effects of Jardian 25 Tablet
Urinary tract infections and female genital mycotic infections are the most common side effects related to Empagliflozin. Dehydration, hypotension, weakness, disorientation, and increased thirst are all typical side effects.
Pregnancy & Lactation
Assessment of renal function is recommended prior to initiation of Empagliflozin and periodically thereafter. Empagliflozin should not initiate in patients with an eGFR less than 45 ml/min/1.73 m2. No dose adjustment is needed in patients with an eGFR greater than or equal to 45 ml/min/1.73 m2.
Precautions & Warnings
Empagliflozin has not been studied in pregnant women in a sufficient and well-controlled manner. Only if the possible benefit outweighs the risk to the fetus should empagliflozin be used during pregnancy. Empagliflozin is not known to be excreted in human milk. It's not a good idea to do it if you're breastfeeding.
Storage Conditions
Keep away from light and moisture in a cool, dry location (below 30° C). Keep out of children's reach.
Disclaimer:
ePharma sole intention is to ensure that its consumers get proper
information as musch as possible. Although we do not guarantee the
accuracy and the completeness of the information that provided and
here information is for informational purposes only.
The information contained herein should NOT be used as a substitute
for the advice of a qualified physician. This may not cover
everything about particular health conditions,
lab tests, medicines, all possible side effects, drug interactions,
warnings, alerts, etc. Please consult your healthcare professional
and discuss all your queries related to any disease or medicine. We
intend to support, not replace, the doctor-patient relationship.